Reflecting on Progress: Aileron Therapeutics’ Second Quarter 2024 Financial Results and Business Highlights
Positive Data from Phase 1b Clinical Trial of LTI-03 A Promising Development in the Treatment of Idiopathic Pulmonary Fibrosis Today, Aileron Therapeutics, Inc. announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial of LTI-03, a potential breakthrough in the treatment of idiopathic pulmonary fibrosis (IPF). The trial evaluated low-dose LTI-03 (2.5…